Cite
HARVARD Citation
Van Herpen, C. et al. (n.d.). 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma. European journal of cancer. pp. S663-. [Online].